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Introduction
Alzheimer’s disease (AD) is characterized by a slow 
continued deterioration of cognitive processes. Th  e  ﬁ  rst 
symptoms of episodic memory disturbances might be 
quite subtle. When the patient is assessed for memory 
problems the disease has most probably been ongoing in 
the brain for several years and has most probably induced 
nonrepairable disturbances of important functional 
neuronal networks and loops of the brain. It is a challenge 
to test whether some of these changes could be reversed 
or slowed down with early drug treatment.
Th   e recent progress in AD research has provided new 
knowledge for further understanding the pathology 
processes of AD that precede the onset of clinical disease 
by many years. It is still an open question why some 
people can cope with AD brain pathology better than 
others. Do they have greater capacity of neuronal com-
pen  sation? Is there ongoing neurogenesis in the brain? 
Th  e resistance toward increased pathological burden 
especially observed in highly educated subjects might be 
a sign of increased brain plasticity as well as greater 
cognitive reserve [1].
Since Dr Alois Alzheimer ﬁ   rst described the AD 
disease, amyloid beta (Aβ) has played a central role in AD 
pathology. It has not yet been proven that Aβ is the 
primary causative factor of AD. A puzzling observation 
from autopsy AD brain studies has been the weak 
correlation between ﬁ  brillar Aβ load in the brain and 
cognition while the amount of neuroﬁ  brillary  tangles 
signiﬁ   cantly correlates with the cognitive status and 
duration of dementia [2-4]. Th  e eﬀ   ects of Aβ in the 
clinical stages of AD are most probably mediated by the 
presence of neuroﬁ  brillary tangles in the brain [5]. In 
addition, a sequential cascade of events including 
oxidative stress reactions, inﬂ   ammatory processes and 
neurotransmitter and receptor dysfunction most 
probably contributes to the impairment of cognitive 
function [6].
Molecular imaging techniques have rapidly developed 
during recent years. Th  is development not only allows 
one to measure brain structural changes in patients 
Abstract
Recent progress in molecular imaging has provided 
new important knowledge for further understanding 
the time course of early pathological disease processes 
in Alzheimer’s disease (AD). Positron emission 
tomography (PET) amyloid beta (Aβ) tracers such as 
Pittsburgh Compound B detect increasing deposition 
of fi  brillar Aβ in the brain at the prodromal stages of 
AD, while the levels of fi  brillar Aβ appear more stable 
at high levels in clinical AD. There is a need for PET 
ligands to visualize smaller forms of Aβ, oligomeric 
forms, in the brain and to understand how they 
interact with synaptic activity and neurodegeneration. 
The infl  ammatory markers presently under 
development might provide further insight into the 
disease mechanism as well as imaging tracers for tau. 
Biomarkers measuring functional changes in the brain 
such as regional cerebral glucose metabolism and 
neurotransmitter activity seem to strongly correlate 
with clinical symptoms of cognitive decline. Molecular 
imaging biomarkers will have a clinical implication in 
AD not only for early detection of AD but for selecting 
patients for certain drug therapies and to test disease-
modifying drugs. PET fi  brillar Aβ imaging together 
with cerebrospinal fl  uid biomarkers are promising as 
biomarkers for early recognition of subjects at risk for 
AD, for identifying patients for certain therapy and for 
quantifying anti-amyloid eff  ects. Functional biomarkers 
such as regional cerebral glucose metabolism together 
with measurement of the brain volumes provide 
valuable information about disease progression and 
outcome of drug treatment.
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magnetic resonance imaging, but also to visualize and 
quantify brain pathology (ﬁ   brillar Aβ, tau, activated 
microglia and astrocytosis) as well as functional changes 
(cerebral glucose metabolism, neurotransmitter and 
neuroreceptor activity) by positron emission tomography 
(PET) (Table 1). Molecular imaging thus provides impor-
tant insight into the ongoing pathological processes in 
AD in relation to clinical symptoms and disease progres-
sion. An important step forward has been in vivo imaging 
of Aβ pathology in AD patients. Although the histo-
patho logical  conﬁ   rma  tion of diagnosis at autopsy is 
impor  tant, it reﬂ  ects the end stage of a disease that may 
have been ongoing for decades.
Th   e new molecular imaging techniques provide possi-
bilities to develop early diagnostic biomarkers for early 
detection of AD at preclinical stages, as well as for 
monitor ing  eﬀ  ects of drug therapy. Recent research has 
thus also changed the view on incorporating biomarkers 
into the standardized clinical diagnosis of AD as suggested 
by Dubois and colleagues [7,8] and the recommendations 
from the National Institute on Aging–Alzheimer 
Association workgroups on diagnostic guidelines for AD 
[9,10].
Amyloid imaging in Alzheimer’s disease patients
Among the ﬁ  rst Aβ PET tracers was Pittsburgh Com-
pound B (11C-PIB) when 16 AD patients were initially 
scanned in Sweden [11]. Th  e  high  11C-PIB retention ob-
served in cortical and subcortical brain regions of mild 
AD patients compared with age-matched healthy sub-
jects has consistently been conﬁ  rmed  with  11C-PIB in 
several other studies (for a review see [12-14]). Several 
other Aβ PET tracers have also been tested in AD and 
control patients [12,15] although so far 11C-PIB is the 
most explored. 18F-labeled tracers will probably be more 
suitable for use in the clinic, with their longer half-life. 
18F-FDDNP was the ﬁ  rst  18F-PET tracer used for 
visualizing Aβ plaque in AD patients [16], showing lower 
binding aﬃ     nity to Aβ plaques than 11C-PIB but also 
suggested to bind to neuroﬁ  brillary tangles [16,17]. Th  e 
18F-labeled Aβ PET tracers 18F-ﬂ  utemetamol, 18F-ﬂ  orbetapir 
and 18F-ﬂ  orbetaben have shown promising results in AD 
patients [18-20].
Th   e PET Aβ tracers quantify ﬁ  brillar Aβ in the brain by 
binding in the nanomolar range to the Aβ peptide [21]. 
Th  e in vivo  11C-PIB retention correlates with 3H-PIB 
binding as well as levels of Aβ measured in autopsy AD 
brain tissue [22-25]. 18F-ﬂ  orbetapir PET imaging has also 
been shown to correlate with the presence of Aβ amyloid 
at autopsy [26], as well as 18F-ﬂ  utemetamol PET imaging 
to amyloid measured in cortical biopsies [27].
A still unknown factor is the relationship between 
ﬁ  brillar Aβ (plaques) and soluble Aβ oligomers. Presently 
there is no information on how the smaller soluble Aβ 
oligomers, which are known for triggering synaptic dys-
function [28-30], can be visualized in vivo in man with 
the presently available Aβ tracers. It is therefore a 
challenge to try to develop PET tracers that can visualize 
these smaller forms of Aβ in the brain, although the 
probably lower content of oligomers in AD brains 
compared with ﬁ  brillar Aβ might be a limiting factor. Th  e 
soluble Aβ oligomers are important since they probably 
can induce and interfere with the neurotransmission in 
the brain [30,31].
Longitudinal PET amyloid studies in Alzheimer’s 
disease patients
Th   ere are still few longitudinal studies of Aβ PET imaging 
in AD patients. Th  ese studies are important to under-
stand the rate of accumulation of amyloid in the brain 
and are important for evaluation of intervention in anti-
amyloid drugs. A 2-year follow-up study with 11C-PIB in 
AD patients revealed at group level consistent stable 
ﬁ  brillar Aβ levels in the brain [32]. Two additional 1-year 
and 2-year follow-up studies conﬁ  rmed these observa-
tions [33,34] as well as a recent 5-year follow-up PET 
study of the ﬁ  rst imaged PIB PET cohort [35]. In the 
latter study it was evident at the individual level that 
increased, stable and decreased PIB retention were 
observed and the disease progression was reﬂ  ected in 
signiﬁ  cant decline in cerebral regional cerebral glucose 
metabolism (rCMRglc) and cognition [35]. In a recent 
20-month follow-up study, Villemagne and colleagues 
reported a 5.7% increase in ﬁ  brillar Aβ in AD patients 
[36]. Th   e longitudinal imaging studies mainly support the 
Table 1. Pathological and functional biomarkers in 
Alzheimer’s disease
Pathological Alzheimer’s disease biomarkers
Positron emission tomography
  Fibrillar amyloid beta (11C-Pittsburgh Compound B, 18F-fl  utemetamol, 
  18F-fl  orbetapir, and 18F-fl  orbetaben)
 Tau  (18F-FDDNP)
 Microglia  (11C-PK11195, 11C-DA1106)
 Astrocytes  (11C-D-deprenyl)
Magnetic resonance imaging (atrophy, hippocampal volume, cortical thickness)
Cerebrospinal fl  uid (amyloid beta 1–42, tau, p-tau)
Functional Alzheimer’s disease biomarkers
Positron emission tomography
  Cerebral glucose metabolism (18F-FDG)
  Neurotransmitter activity (for example, 11C-CFT, 11C-PMP)
  Neuroreceptors (for example, 11C-raclopride, 18F-alanserine, 11C-nicotine)
Functional magnetic resonance imaging, spectroscopy 
Single-photon emission computed tomography (cerebral blood fl  ow)
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maximal level at the early clinical stage of the disease, 
although both increase and decline in later stages of the 
disease cannot be excluded [12,37,38].
Amyloid imaging in mild cognitive impairment 
patients
11C-PIB PET studies in mild cognitive impairment (MCI) 
patients have revealed a bimodal distribution. Both high 
(PIB+) and low (PIB–) retention of the PET tracer has 
been demonstrated [39,40]. PIB+ MCI patients seem to 
have a greater risk to convert to AD after clinical follow-
up compared with PIB– MCI patients [39,41,42]. Figure 1 
illustrates high 11C-PIB retention in a MCI patient (PIB+) 
who later converted to AD in comparison with a non-
converting MCI patient (PIB–). PIB+ MCI patients show 
comparably high11C-PIB retention to AD patients 
(Figure 1). We recently observed a signiﬁ  cant increase in 
brain  11C-PIB retention in early MCI patients when re-
scanned after 3 years [35]. Th   e MCI patients also showed 
a decrease in rCMRglc while they remained stable in 
cognitive function at follow-up [35]. Jack and colleagues 
[34] and Villemagne and colleagues [36] have also 
reported annual changes in 11C-PIB retention. Th  ese 
ﬁ  ndings support a continuous increase in Aβ load in the 
early stage of prodromal AD [35] (Figure 2).
Amyloid imaging in older subjects without 
cognitive impairment
High Aβ has been measured in older cognitive normal 
controls (for a review see [43]). Th   e reported percentage 
of positive Aβ PET scans varies from 10 to 50% between 
diﬀ  erent cohorts of studied older people without cog  ni-
tive impairment [44,45]. A possible explanation for 
variation in percentage of Aβ PET-positive cognitive 
normal subjects could be age but also genetic background 
(APOE genotype). Aβ alone most probably does not 
account for the decline in memory in older people. 
Further longitudinal studies are needed to investigate to 
what extent these Aβ-positive older people with normal 
cognition will later convert to AD [46]. In a recent 
longitudinal study of 159 older subjects with normal 
cognition and PIB+, PET showed a greater risk for 
developing symptomatic AD within 2 to 5  years 
compared with PIB– subjects [47].
Relationship between brain amyloid and 
cerebrospinal fl  uid biomarkers
Th  ere is a strong inverse correlation between accumu-
lations of ﬁ  brillar Aβ in the brain as measured by 11C-PIB 
and levels of Aβ1–42 in cerebrospinal ﬂ  uid (CSF) [39,48-55]. 
An inverse correlation between 11C-PIB retention and 
CSF Aβ1–42 has been demonstrated in prodromal AD 
(MCI) earlier than changes in functional parameters 
(cerebral glucose metabolism, cognition) [54] (Figure 2). 
Figure 3 illustrates the inverse relationship between Aβ in 
the brain and the CSF as analyzed with statistical para-
metric mapping cluster analysis. A positive relation  ship 
has also been observed between 11C-PIB retention and 
levels of CSF tau and p-tau [39,50,51,54]. Which of the 
biomarkers are most sensitive to detect the earliest 
pathological signs of the disease is still unclear.
Some data suggest that 11C-PIB PET imaging detects 
amyloid pathology prior to CSF biomarkers [39,49,54]. 
Soluble Aβ oligomers might be the most pathogenic in 
AD. An interesting observation is therefore that AD 
patients with the APP arctic mutation show no ﬁ  brillar 
Aβ in the brain (PIB-negative) but a reduction of Aβ42 in 
CSF as well as a reduction in cerebral glucose 
metabolisms by PET [56].
Imaging of infl  ammatory processes in Alzheimer’s 
disease brain
Inﬂ  ammatory processes have been suggested to cause the 
pathological processes of AD [57,58]. Amyloid has been 
observed to mobilize and activate microglia [59]. 
Activated microglia are found in autopsy brain tissue at 
Figure 1. Pittsburgh Compound B retention in the brain. 
Pittsburgh Compound B (11C-PIB) retention in the brain of a healthy 
control (HC), an Alzheimer patient (AD), patients with mild cognitive 
impairment (MCI) who later at clinical follow-up converted to AD, 
and patients with MCI who did not later convert to AD. PIB+, high 
Pittsburgh Compound B retention; PIB–, low Pittsburgh Compound 
B retention. Red, high 11C-PIB retention; yellow, medium 11C-PIB 
retention; blue, low 11C-PIB retention.
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peripheral benzodiazepine receptor PET tracer 11C-(R)-
PK11195 has been used for measuring the transition of 
microglia from a resting state to an activated state in the 
brain. An increase in 11C-(R)-PK11195 binding was 
described by Cagnin and colleagues in the 
temporoparietal, cingulated and ento  rhinal cortices of 
AD patients as a sign for strong micro  glia activation 
compared with controls [60]. Edison and colleagues 
demonstrated high cortical 11C-(R)-PK11195 binding 
with reciprocal negative correlation with cogni  tive 
performance in AD patients [61]. In some other studies, a 
lower level of microglia activation was observed in mild 
AD and MCI [62,63]. 11C-DAA-1106 is a new peripheral 
benzodiazepine PET tracer that has shown increased 
binding in several brain regions including the frontal, 
parietal, temporal cortices and striatum of AD patients 
compared with age-matched controls [64].
Activated astrocytes participate in the inﬂ  ammatory 
processes occurring around the Aβ plaques. An increased 
number of astrocytes have been measured in autopsy 
brain tissue from AD patients, especially those with the 
Swedish APP mutation [65]. A positive correlation has 
been observed between 3H-PIB binding and GFAP 
immunoreactivity in autopsy AD brain tissue [25]. It is 
assumed that synaptic activity might be coupled to 
utilization of energy through an interaction between 
astrocytes and neurons where the astrocytes take up 
glucose and release lactate to neurons [66].
N-[11C-methyl]-l-deuterodeprenyl (11C-DED) has been 
shown to irreversibly bind to the enzyme monoamino-
oxidase B expressed in reactive astrocytes. 11C-DED has 
therefore been tested as a PET ligand for measurement of 
activated astrocytes. Increased 11C-DED binding was demon-
strated in the brain of patients with Creutzfeldt–Jacob 
disease [67]. We have recently observed by PET an 
increased 11C-DED binding in the cortical and subcortical 
brain regions of MCI patients compared with AD patients 
and controls [68]. Th   ese observations suggest that 
astrocytosis might be a very early event in the time course 
of pathological processes in AD (Figure 2). Further studies 
are needed to explore the relationship between Aβ and 
inﬂ  ammatory processes in the early stages of AD.
Imaging of functional changes in Alzheimer’s 
disease brain
Brain glucose metabolism
2-[18F]-ﬂ  uoro-2-deoxy-d-glucose  (18F-FDG) has been 
widely used both in research and clinically for measure-
ment of regional changes in rCMRglc in AD [10]. A 
reduction of rCMRglc is often observed in the parietal, 
temporal, frontal and posterior cingulate cortices. Th  e 
decline in rCMRglc is more regional speciﬁ  c compared 
with the increased 11C-PIB retention in large areas of the 
AD brain [11,32]. Th  e hypometabolism is often more 
severe in early-onset AD compared with late-onset AD, 
while no diﬀ  erence in regional 11C-PIB retention has been 
observed between early-onset and late-onset AD [69]. 
11C-PIB PET seems to detect prodromal AD at an earlier 
disease stage and better separates between MCI subtypes 
(amnestic versus nonamnestic) than 18F-FDG [39,58,70]. 
Th  e decline in rCMRglc follows, in contrast to PIB, the 
clinical progression of AD and shows a strong correlation 
with changes in cognition [32,35,58,70]. Figure 3 illus-
trates the correlation between rCMRglc and episodic 
memory (Rey Auditory Verbal Learning) and between 
11C-PIB and episodic memory (Rey Auditory Verbal 
Learning) as analyzed with statistical parametric map-
ping analysis. Th  e 18F-FDG uptake shows more brain 
regional speciﬁ  c clusters compared with 11C-PIB [54].
Figure 2. Schematic drawing of changes in pathological and functional imaging markers during progression of Alzheimer’s disease. 
Aβ, amyloid beta; AD, Alzheimer’s disease; CSF, cerebrospinal fl  uid; MCI, mild cognitive impairment.
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Several neurotransmitters are impaired in AD, especially 
the cholinergic system but also the dopaminergic and 
serotonergic neurotransmitter. Several PET tracers have 
been developed and tested for measuring the diﬀ  erent 
neurotransmitters, enzymes and various subtypes of 
receptors in AD patients [10]. PET tracers are available 
for studying dopaminergic, serotonergic and cholinergic 
systems [12] (Table 1). Th   e cholinergic neurotransmission 
has so far been the focus for clinical AD therapy. It is 
therefore worth mentioning that decreases in nicotinic 
receptors have been demonstrated by PET in AD patients 
using  11C-nicotine [71] and 18F-ﬂ  uoro-A-85380  (α4 
nicotinic receptors) [72]. Th  e extent of reduction in 
11C-nicotine binding correlated with the reduction in 
level of attention of the AD patients [71]. Presently there 
is a great interest to develop selective PET tracers for 
imaging of the α7 nicotinic receptors in the brain since 
these receptors interact with Aβ and might therefore be a 
new target for AD therapy [73].
Imaging biomarkers and drug development
Recent progress in molecular imaging and biomarkers 
indicates that subtle pathological changes indicative for 
AD disease might be detected decades prior to clinical 
diagnosis of AD. Diﬀ   erences in the time course are 
observed between pathological and functional AD imag-
ing biomarkers (Figure 2). PET imaging allows measure-
ment of pathological processes such as depo  sition of 
ﬁ   brillar Aβ plaques, levels of activated microglia and 
astrocytosis. Th  ere is a need for further exploration of 
PET tracers visualizing inﬂ   ammatory processes that 
might occur at very early disease states (Figure 2). Simi-
larly, there is a great need for PET tracers visualizing the 
accumulation of Aβ oligomers in diﬀ  erent stages of AD 
(Figure 2). Preclinical data for the new promising PET 
ligand THK 523 for in vivo tau imaging have recently 
been presented [74]. Additional PET studies are needed 
to predict with more accuracy the time course for 
changes in neurotransmitter function including the nico-
tinic receptors. Brain atrophy changes (magnetic reso-
nance imaging) correlate closely with cognitive decline 
and disease progression but less with amyloid load in the 
brain [14,20,75].
Th  e rapid development of molecular imaging will be 
important not only for early diagnostic biomarkers and 
early detection of AD [7-9,46] but also to select patients 
for certain drug therapies and to identify disease-
modifying therapies and testing in clinical trials (Table 2). 
PET imaging bio  markers could thereby play an important 
role in identifying patients with elevated risk of 
developing AD. In addition, ﬁ  brillar Aβ imaging could 
(together with CSF Aβ42) serve as an inclusion criterion 
as well as a primary outcome in phase 2 and a secondary 
outcome in phase 3 drug trials. Measurement of rCMRglc 
and magnetic resonance imaging atrophy changes are 
probably most useful for predicting the clinical outcomes 
of drug therapy.
Th  e multi-tracer PET concept oﬀ   ers unique oppor-
tunities in drug trials to study pathological as well as 
functional processes and to relate these processes in the 
brain to CSF biomarkers and cognitive outcomes 
(Figure 4). Th   ere is now an increased interest to introduce 
diﬀ  erent biomarkers into clinical trials in AD patients 
[76], which will be important for all drug candidates in 
the pipeline for AD trials [77]. Long-term treatment with 
cholinesterase inhibitors in AD patients has shown 
signiﬁ  cant correlation between the degree of inhibition 
Figure 3. Positron emission tomography measurements, cerebrospinal fl  uid amyloid beta 1–42 and episodic memory scores. Statistical 
parametric mapping analysis showing clusters with signifi  cant covariance between positron emission tomography measurements versus levels 
of cerebrospinal fl  uid (CSF) amyloid beta 1–42 (Aβ1–42) and episodic memory scores measured by means of Rey Auditory Verbal Learning (RAVLtot) 
tests, using data from Alzheimer’s disease and mild cognitive impairment patients, at threshold P <0.001, uncorrected for multiple comparisons. 
(a) Areas with signifi  cant covariance between Pittsburgh Compound B (11C-PIB) retention and concentrations of Aβ1–42 in CSF. (b) Clusters with 
signifi  cant covariance between 11C-PIB retention and scores in RAVLtot tests. (c) Signifi  cant clusters of covariance between regional cerebral glucose 
metabolism (rCMRglc) and scores in RAVLtot tests. Data from [54].
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nicotinic receptors, rCMRglc and clinical outcome of 
treatment measured as attentional test performances 
[78-82]. To evaluate the eﬀ  ect of new disease-modifying 
thera  peutics, imag  ing of ﬁ   brillar amyloid, activated 
microglia, astrocytosis, tau in addition to rCMRglc and 
structural brain changes should be applied to determine 
whether anti-amyloid strategies may clear the amyloid 
plaques from the brain but also slow down disease 
progression. A few PET studies in AD patients have 
shown reduction of brain Aβ measured by 11C-PIB 
following anti-amyloid treatment [81,83,84] but the 
disease-modifying eﬀ  ects still have to be proven.
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